Psoriatic Arthritis

GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis
Elsa Vieira-Sousa, Pedro Alves, Ana M Rodrigues, Filipa Teixeira, Jose Tavares-Costa, Alexandra Bernardo, Sofia Pimenta, Fernando M Pimentel-Santos, João Lagoas Gomes, Renata Aguiar, Patrícia Pinto, Taciana Videira, Cristina Catita, Helena Santos, Joana Borges, Graça Sequeira, Célia Ribeiro, Lídia Teixeira, Pedro Ávila- Ribeiro, Fernando M Martins, Helena Canhão, Iain B. McInnes, Ruy M Ribeiro, João Eurico Fonseca

Annals of the Rheumatic Diseases Apr 2020, 79 (4) 490-498; DOI: 10.1136/annrheumdis-2019-216500
Differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis
Margarida Souto-Carneiro, Lilla Tóth, Rouven Behnisch, Konstantin Urbach, Karel D Klika, Rui A Carvalho, Hanns-Martin Lorenz

Annals of the Rheumatic Diseases Apr 2020, 79 (4) 499-506; DOI: 10.1136/annrheumdis-2019-216374
Secukinumab efficacy in patients with PsA is not dependent on patients’ body mass index
Ilenia Pantano, Daniela Iacono, Ennio Giulio Favalli, Giuseppe Scalise, Luisa Costa, Francesco Caso, Giuliana Guggino, Raffaele Scarpa, Francesco Ciccia

Annals of the Rheumatic Diseases Mar 2020, annrheumdis-2020-217251; DOI: 10.1136/annrheumdis-2020-217251
Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden
Tine Iskov Kopp, Bénédicte Delcoigne, Elizabeth V Arkema, Rikke Kart Jacobsen, Melinda Magyari, Else Helene Ibfelt, Henning Locht, Finn Sellebjerg, Rene Lindholm Cordtz, Dorte V Jensen, Johan Askling, Lene Dreyer

Annals of the Rheumatic Diseases Mar 2020, annrheumdis-2019-216693; DOI: 10.1136/annrheumdis-2019-216693
Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis
Xintong Li, Kathleen M Andersen, Hsien-Yen Chang, Jeffrey R Curtis, G Caleb Alexander

Annals of the Rheumatic Diseases Feb 2020, 79 (2) 285-291; DOI: 10.1136/annrheumdis-2019-216102
Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching
Fabrizio Cantini, Maurizio Benucci

Annals of the Rheumatic Diseases Feb 2020, 79 (2) e13; DOI: 10.1136/annrheumdis-2018-214757
Enrichment of polyfunctional T cells in PsA synovial tissue. Response to: ‘Polyfunctional TEM cells in psoriatic arthritis synovium skewed towards Th17 cells’ by Raychaudhuri et al
Mary Canavan, Sarah M Wade, Douglas J Veale, Ursula Fearon

Annals of the Rheumatic Diseases Jan 2020, annrheumdis-2019-216814; DOI: 10.1136/annrheumdis-2019-216814
Polyfunctional TEM cells in psoriatic arthritis synovium skewed towards Th17 cells
Smriti K Raychaudhuri, Christine Abria, Siba P Raychaudhuri

Annals of the Rheumatic Diseases Dec 2019, annrheumdis-2019-216658; DOI: 10.1136/annrheumdis-2019-216658
Greetings from the editor 2020
Josef S Smolen

Annals of the Rheumatic Diseases Jan 2020, 79 (1) 1-2; DOI: 10.1136/annrheumdis-2019-216758
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
Philip J Mease, Josef S Smolen, Frank Behrens, Peter Nash, Soyi Liu Leage, Lingnan Li, Hasan Tahir, Melinda Gooderham, Eswar Krishnan, Hong Liu-Seifert, Paul Emery, Sreekumar G Pillai, Philip S Helliwell

Annals of the Rheumatic Diseases Jan 2020, 79 (1) 123-131; DOI: 10.1136/annrheumdis-2019-215386

Main menu

Psoriatic Arthritis

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Psoriatic Arthritis

Pages